002432 九安医疗
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入762,297-49.03%3,231,12526,315,3612,397,0982,008,360
减:营业总成本473,480-39.76%2,186,3117,434,7301,447,6841,572,994
    其中:营业成本216,480-55.93%1,176,5725,367,195875,549877,505
               财务费用7,981-111.51%(199,522)(209,149)2,60218,784
               资产减值损失(1,335)-94.49%(309,867)(321,559)(9,274)(177,698)
公允价值变动收益(113,556)-185.47%309,288(326,401)30,489(335,946)
投资收益175,80246.76%560,73893,48345,583317,541
    其中:对联营企业和合营企业的投资收益0--(1,679)(1,266)(1,380)(332)
营业利润350,291-61.37%1,613,49118,311,8691,002,549238,588
利润总额349,036-61.45%1,580,34418,257,857999,632239,753
减:所得税费用38,557-79.72%231,1121,773,76365,2292,925
净利润310,479-56.58%1,349,23216,484,094934,403236,828
减:非控股权益63,050-44.52%97,624453,92525,761(5,501)
股东净利润247,429-58.86%1,251,60816,030,169908,642242,329

市场价值指针
每股收益 (元) *0.557-56.39%2.81535.1381.9990.560
每股派息 (元) *----0.3002.5000.7000.060
每股净资产 (元) *38.341-7.12%39.38140.3575.9674.355
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容